In a report released today, Steven Lichtman from Oppenheimer maintained a Buy rating on Integra Lifesciences (NASDAQ: IART). The company’s shares opened today at $54.50.
According to TipRanks.com, Lichtman is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -3.3% and a 50.0% success rate. Lichtman covers the Healthcare sector, focusing on stocks such as Boston Scientific Corp, Zimmer Biomet Holdings, and Motus Gi Holdings Inc.
The word on The Street in general, suggests a Hold analyst consensus rating for Integra Lifesciences with a $65.50 average price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $67.50 and a one-year low of $45.96. Currently, Integra Lifesciences has an average volume of 598.5K.
Based on the recent corporate insider activity of 76 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Integra LifeSciences Holdings Corp. engages in the manufacture and sale of medical instruments, devices, and equipment. It operates through the Codman Specialty Surgical and Orthopedics and Tissue Technologies segments.
